relebactam (Recarbrio) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Relebactum sodium (MK-7655) is a piperidine analog 3 that inhibits class A and C β-lactamases (in vitro). It is being investigated for use in treatment of infectious diseases, such as treatment of gram-negative bacterial infections. Its potential as an alternative to existing medicines in the treatment of drug-resistant bacterial infections is being studied. Clinical trials have been conducted and are still ongoing to evaluate the efficacy and safety of relebactum sodium in treatment of intra-abdominal infections, urinary tract infections (such as pyelonephritis), hospital-acquired and ventilator-associated bacterial pneumonias, and gram-negative bacterial infections.   NCATS

  • SMILES: OS(=O)(=O)ON1[C@@H]2CC[C@H](N(C2)C1=O)C(=O)NC3CCNCC3
  • Mol. Mass: 348.38
  • ALogP: -1.14
  • ChEMBL Molecules:
More Chemistry

Combination drugs

( cilastatin (primaxin), relebactam (Recarbrio), imipenem (primaxin) - other name: imipenem/cilastatin/relebactam )
mk-7655 | relebactam | relebactam anhydrous


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue